methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate | 118235-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate
• 英文别名: 3-[(ethoxycarbonyl)amino]thiophene-2-carboxylic acid methyl ester；methyl 3-ethoxycarbonylaminothiophene-2-carboxylate；3-ethoxycarbonylamino-thiophene-2-carboxylic acid methyl ester；methyl 3-(ethoxycarbonylamino)-thiophen-2-carboxylate；Methyl 3-(ethoxycarbonylamino)thiophene-2-carboxylate
• CAS: 118235-88-4
• 化学式: C₉H₁₁NO₄S
• mdl: MFCD00278332
• 分子量: 229.257
• InChiKey: KCJYKWHUIACPDK-UHFFFAOYSA-N

物化性质

• 熔点：
  63.5-65.5 °C
• 沸点：
  301.9±27.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate 在 肼 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 3-amino-1H-thieno[3,2-d]pyrimidine-2,4-dione
  参考文献：
  名称：

  Thieno-and furo-pyrimidine modulators of the histamine H4 receptor

  摘要：

  描述了噻吩-和呋喃-嘧啶化合物，这些化合物可用作H4受体调节剂。这些化合物可以用于制药组合物和用于调节组胺H4受体活性以及治疗由H4受体活性介导的疾病状态、紊乱和条件的方法，如炎症。

  公开号：

  US20090075970A1
• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸甲酯 、 氯甲酸乙酯 以 甲苯 为溶剂， 反应 2.0h， 以92%的产率得到methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate
  参考文献：
  名称：

  一种新型的杂环化合物。恶唑并[3，2-a]噻吩并[3，2-d]-嘧啶衍生物的合成和反应性。

  摘要：

  分两步开发了由3-氨基噻吩-2-羧酸甲酯制备2,3-二氢-5H-恶唑并[3,2-a]噻吩并[3,2-d]嘧啶-5-酮（2）的实用方法。 。研究了各种亲核试剂与2的加成反应，并生成了恶唑开环的化合物（5、6、12、13和14）。2与阮内镍的脱硫反应得到恶唑啉[3,2-a]嘧啶衍生物（15）。发现2显示出有效的抗胃分泌活性。

  DOI：

  10.1248/cpb.37.1197

文献信息

• [EN] THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE<br/>[FR] CARBOXAMIDES DE THIÉNOPYRIDONE ET LEUR UTILISATION MÉDICALE
  申请人：ACTIVE BIOTECH AB

  公开号：WO2005123744A1

  公开（公告）日：2005-12-29

  A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R´ is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R´´ is hydrogen, fluoro or chloro, that R´´ being fluoro or chloro only when R´ is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl, R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4´ wherein R4´ is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C-R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.

  式（I）的化合物，其中R是甲基、乙基、正丙基、异丙基、正丁基或烯丙基；R´是氢、C1-C4烷基、C1-C3烷氧基、卤素、三氟甲基或OCHxFy；R´´是氢、氟或氯，当R´是氟或氯时，R´´仅为氟或氯；R3是氢或C1-C5烷基，R4是氢、CH2OCOC(CH3)3、药学上可接受的无机或有机阳离子，或COR4´，其中R4´是C1-C5烷基、苯基、苄基或苯乙基；R7是甲基或乙基；A和B中的一个是硫，另一个是C-R2；当A为S时，R2从氢和甲基中选择，但R2仅当R3不是氢时为甲基；当B为S时，R2为氢；及其任何互变异构体。包括式（I）的化合物的药物组合物，一种治疗恶性肿瘤或由自身免疫或病理性炎症引起的疾病的方法。
• Modified aminoacids, pharmaceuticals containing these compounds and method for their production
  申请人：Dr. Karl Thomae GmbH

  公开号：US06344449B1

  公开（公告）日：2002-02-05

  The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式的改性氨基酸 其中 A、Z、X、n、m、R、R2、R3、R4和R11的定义如权利要求1至5中所述，它们的互变异构体、对映异构体、立体异构体、它们的混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及制备它们的过程，以及它们在抗体的生产和纯化中的用途以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20010036946A1

  公开（公告）日：2001-11-01

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改良氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5中所定义，它们的互变异构体、对映异构体、混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及用于制备它们的过程，以及它们在抗体的生产和纯化中的用途，以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• Condensed thienopyrimidines. I. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidin-5-one derivatives.
  作者：Mitsuo SUGIYAMA、Toshiaki SAKAMOTO、Keiichi TABATA、Kazuo ENDO、Keiichi ITO、Mitsuko KOBAYASHI、Hiroshi FUKUMI

  DOI：10.1248/cpb.37.2091

  日期：——

  A practical preparation of various 2, 3-dihydro-5H-oxazolo[3, 2-a]thieno[3, 2-d]-, [3, 4-d]-, and [2, 3-d]pyrimidin-5-one derivatives was developed starting from the corresponding aminothiopheneesters in two steps, and their chloro-substituted derivatives were prepared. These compounds were evaluated for gastric antisecretory activity in pylorus-ligated rats, compared to the anti-ulcer standard, cimetidine, and their structure-activity relationships are discussed.

  一种实用的方法被开发用于合成多种2, 3-二氢-5H-噁唑并噻吩的[3, 2-a]、[3, 4-d]和[2, 3-d]嘧啶-5-酮衍生物，该过程从相应的氨基噻吩酯出发，仅需两步，并且其氯取代衍生物也被合成。这些化合物在幽门结扎大鼠中评估了其抗胃分泌活性，并与抗溃疡标准药物西咪替丁进行了比较，同时讨论了它们的结构-活性关系。
• A novel heterocyclic compound. Synthesis and reactivities of an oxazolo(3,2-a)thieno(3,2-d)-pyrimidine derivative.
  作者：Hiroshi FUKUMI、Mitsuo SUGIYAMA、Toshiaki SAKAMOTO

  DOI：10.1248/cpb.37.1197

  日期：——

  arboxylate in two steps was developed. The addition reactions of various nucleophiles to 2 were investigated and oxazole-ring-opened compounds were produced (5, 6, 12, 13 and 14). Desulfurization reaction of 2 with Raney Ni gave an oxazolo[3,2-a]pyrimidine derivative (15). It was found that 2 showed potent anti-gastric secretion activity.

  分两步开发了由3-氨基噻吩-2-羧酸甲酯制备2,3-二氢-5H-恶唑并[3,2-a]噻吩并[3,2-d]嘧啶-5-酮（2）的实用方法。 。研究了各种亲核试剂与2的加成反应，并生成了恶唑开环的化合物（5、6、12、13和14）。2与阮内镍的脱硫反应得到恶唑啉[3,2-a]嘧啶衍生物（15）。发现2显示出有效的抗胃分泌活性。